Test ID URIC Uric Acid, Serum
Useful For
Diagnosis and treatment of renal failure and monitoring patients receiving cytotoxic drugs and a variety of other disorders, including gout, leukemia, psoriasis, starvation and other wasting conditions
Method Name
Photometric, Uricase/Quinone-Imine Dye Formation
Reporting Name
Uric Acid, SSpecimen Type
SerumContainer/Tube:
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 0.5 mL
Collection Instructions:
1. Serum gel tubes should be centrifuged within 2 hours of collection.
2. Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.
Additional Information: Patient's age and sex are required.
Specimen Minimum Volume
0.25 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Refrigerated (preferred) | 7 days |
Frozen | 180 days |
Clinical Information
Uric acid is the final product of purine metabolism in humans. Purines, compounds that are vital components of nucleic acids and coenzymes, may be synthesized in the body or they may be obtained by ingesting foods rich in nucleic material (eg, liver, sweetbreads). Approximately 75% of the uric acid excreted is lost in the urine; most of the remainder is secreted into the gastrointestinal tract, where it is degraded to allantoin and other compounds by bacterial enzymes.
Asymptomatic hyperuricemia is frequently detected through biochemical screening. The major causes of hyperuricemia are increased purine synthesis, inherited metabolic disorder, excess dietary purine intake, increased nucleic acid turnover, malignancy, cytotoxic drugs, and decreased excretion due to chronic renal failure or increased renal reabsorption. Long-term follow-up of these patients is undertaken because many are at risk of developing renal disease; few of these patients ever develop the clinical syndrome of gout.
Hypouricemia, often defined as serum urate <2.0 mg/dL, is much less common than hyperuricemia. It may be secondary to severe hepatocellular disease with reduced purine synthesis, defective renal tubular reabsorption, overtreatment of hyperuricemia with allopurinol, as well as some cancer therapies (eg, 6-mercaptopurine).
Reference Values
Males
1-10 years: 2.4-5.4 mg/dL
11 years: 2.7-5.9 mg/dL
12 years: 3.1-6.4 mg/dL
13 years: 3.4-6.9 mg/dL
14 years: 3.7-7.4 mg/dL
15 years: 4.0-7.8 mg/dL
≥16 years: 3.7-8.0 mg/dL
Reference values have not been established for patients who are <12 months of age.
Females
1 year: 2.1-4.9 mg/dL
2 years: 2.1-5.0 mg/dL
3 years: 2.2-5.1 mg/dL
4 years: 2.3-5.2 mg/dL
5 years: 2.3-5.3 mg/dL
6 years: 2.3-5.4 mg/dL
7-8 years: 2.3-5.5 mg/dL
9-10 years: 2.3-5.7 mg/dL
11 years: 2.3-5.8 mg/dL
12 years: 2.3-5.9 mg/dL
≥13 years: 2.7-6.1 mg/dL
Reference values have not been established for patients who are <12 months of age.
Cautions
The following drugs cause interference (falsely decreased levels) at therapeutic concentrations:
-Alpha-methyldopa
-Desferoxamine
-Calcimdobesilate
Result can be falsely decreased in patients with elevated levels of N-acetyl-p-benzoquinone imine (NAPQI, a metabolite of acetaminophen), N-acetylcysteine (NAC), and Metamizole.
Day(s) Performed
Monday through Sunday; Continuously
Report Available
Same day/1 dayPerforming Laboratory

Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
84550